Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Sarcoma 3Sarcoma, Alveolar Soft Part 2Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Rhabdomyosarcoma 1Oligodendroglioma 1Neurofibrosarcoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Gliosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Fibrosarcoma 1Endometrial Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 32Radiotherapy 11Magnetic Resonance Spectroscopy 11Carboplatin 10Bevacizumab 10Irinotecan 9Carmustine 9Filgrastim 8Erlotinib Hydrochloride 8Surgical Procedures, Operative 7sargramostim 5Imatinib Mesylate 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5temsirolimus 4Vorinostat 4Sirolimus 4Procarbazine 4Peripheral Blood Stem Cell Transplantation 4O(6)-benzylguanine 4aldesleukin 3Thalidomide 3Iodine-125 3Immunohistochemistry 3Gadolinium DTPA 3Cyclophosphamide 3Bortezomib 3Biopsy 3lonafarnib 2imetelstat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × perifosine × Sarcoma × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡